Sean Lee
Stock Analyst at HC Wainwright & Co.
(4.29)
# 466
Out of 4,749 analysts
71
Total ratings
37.5%
Success rate
33.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Maintains: Buy | $22 → $40 | $43.94 | -8.97% | 9 | Jan 22, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Buy | $11 | $5.36 | +105.22% | 2 | Jan 14, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $11.79 | +69.64% | 11 | Jan 14, 2025 | |
| VSTM Verastem | Reiterates: Buy | $7 | $6.08 | +15.13% | 12 | Dec 19, 2024 | |
| PSTV Plus Therapeutics | Reiterates: Buy | $8 | $1.24 | +545.16% | 10 | Nov 26, 2024 | |
| MYO Myomo | Reiterates: Buy | $7.5 | $6.03 | +24.38% | 4 | Nov 13, 2024 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $1.01 | -0.50% | 11 | Nov 11, 2024 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $1.58 | +1,165.82% | 4 | Jul 12, 2024 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $12 → $6 | $2.48 | +142.42% | 7 | May 15, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $1.09 | +2,652.29% | 1 | Dec 5, 2022 |
Monopar Therapeutics
Jan 22, 2025
Maintains: Buy
Price Target: $22 → $40
Current: $43.94
Upside: -8.97%
Corvus Pharmaceuticals
Jan 14, 2025
Reiterates: Buy
Price Target: $11
Current: $5.36
Upside: +105.22%
Alphatec Holdings
Jan 14, 2025
Reiterates: Buy
Price Target: $20
Current: $11.79
Upside: +69.64%
Verastem
Dec 19, 2024
Reiterates: Buy
Price Target: $7
Current: $6.08
Upside: +15.13%
Plus Therapeutics
Nov 26, 2024
Reiterates: Buy
Price Target: $8
Current: $1.24
Upside: +545.16%
Myomo
Nov 13, 2024
Reiterates: Buy
Price Target: $7.5
Current: $6.03
Upside: +24.38%
Cytosorbents
Nov 11, 2024
Reiterates: Neutral
Price Target: $1
Current: $1.01
Upside: -0.50%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $1.58
Upside: +1,165.82%
CASI Pharmaceuticals
May 15, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $2.48
Upside: +142.42%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $1.09
Upside: +2,652.29%